Patents by Inventor Genmin Lu

Genmin Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 10765726
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 8, 2020
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20200276280
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: May 7, 2020
    Publication date: September 3, 2020
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • PREPARATION OF FACTOR XA DERIVATIVES
    Publication number: 20200208131
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 2, 2020
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • Antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 10675335
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 9, 2020
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • MODULATION OF FACTOR Xa INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
    Publication number: 20200129597
    Abstract: The present disclosure provides unit dose formulations and methods to reduce, stop or prevent bleeding in a patient undergoing anticoagulant therapy with a factor Xa inhibitor. The methods entail at least partial neutralization of the factor Xa inhibitors. The unit dose formulations and methods of the present disclosure can be effective even after actual bleeding has initiated.
    Type: Application
    Filed: July 23, 2019
    Publication date: April 30, 2020
    Inventors: Stanley J. Hollenbach, Genmin Lu, Uma Sinha
  • Preparation of factor Xa derivatives
    Patent number: 10604748
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: March 31, 2020
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20190309279
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: January 17, 2019
    Publication date: October 10, 2019
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
  • PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR
    Publication number: 20190127720
    Abstract: Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide.
    Type: Application
    Filed: September 11, 2018
    Publication date: May 2, 2019
    Inventors: Genmin Lu, Pamela B. Conley, Uma Sinha
  • Antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 10190111
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: January 29, 2019
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
  • INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES
    Publication number: 20180333469
    Abstract: The present disclosure relates to compositions and methods for the treatment of bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand (vWF) disease, and factor XII deficiency, by reducing the circulating concentration of tissue factor pathway inhibitor (TFPI), with a factor Xa derivative.
    Type: Application
    Filed: March 12, 2018
    Publication date: November 22, 2018
    Inventors: Genmin Lu, Uma Sinha, Mark Karbarz, Anjali Pandey, Pamela B. Conley
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20180236049
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: December 6, 2017
    Publication date: August 23, 2018
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • MODULATION OF FACTOR Xa INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
    Publication number: 20180185459
    Abstract: The present disclosure provides unit dose formulations and methods to reduce, stop or prevent bleeding in a patient undergoing anticoagulant therapy with a factor Xa inhibitor. The methods entail at least partial neutralization of the factor Xa inhibitors The unit dose formulations and methods of the present disclosure can be effective even after actual bleeding has initiated.
    Type: Application
    Filed: February 22, 2018
    Publication date: July 5, 2018
    Inventors: Stanley J. Hollenbach, Genmin Lu, Uma Sinha
  • PREPARATION OF FACTOR XA DERIVATIVES
    Publication number: 20170369862
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Application
    Filed: June 19, 2017
    Publication date: December 28, 2017
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR
    Publication number: 20170240879
    Abstract: Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide.
    Type: Application
    Filed: December 27, 2016
    Publication date: August 24, 2017
    Inventors: Genmin Lu, Pamela B. Conley, Uma Sinha
  • ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20170233711
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 17, 2017
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
  • Antidotes for factor XA inhibitors and methods of using the same
    Patent number: 9587233
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: March 7, 2017
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20170014492
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: July 15, 2016
    Publication date: January 19, 2017
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20160354449
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 8, 2016
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • Antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 9388401
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: July 12, 2016
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20160002617
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 7, 2016
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley